Alluvi, previously BI 4744, presents a notable development in obesity treatment. This dual stimulator targeting both GLP-1 and GIP receptors demonstrates remarkable efficacy in clinical trials, possibly surpassing https://thesocialcircles.com/story7976134/alluvi-a-comprehensive-examination-into-retatrutide-s-possibilities